Your browser doesn't support javascript.
loading
Mean GH profile is more accurate than single fasting GH in the evaluation of acromegaly disease control during somatostatin receptor ligands therapy.
Bona, C; Prencipe, N; Berton, A M; Bioletto, F; Parasiliti-Caprino, M; Gasco, V; Ghigo, E; Grottoli, S.
Afiliación
  • Bona C; Division of Endocrinology, Diabetology and Metabolism, Medical Science Department, University Hospital "Città della Salute e della Scienza di Torino", Corso Dogliotti 14, 10126, Turin, Italy. chiara.bona@unito.it.
  • Prencipe N; Division of Endocrinology, Diabetology and Metabolism, Medical Science Department, University Hospital "Città della Salute e della Scienza di Torino", Corso Dogliotti 14, 10126, Turin, Italy.
  • Berton AM; Division of Endocrinology, Diabetology and Metabolism, Medical Science Department, University Hospital "Città della Salute e della Scienza di Torino", Corso Dogliotti 14, 10126, Turin, Italy.
  • Bioletto F; Division of Endocrinology, Diabetology and Metabolism, Medical Science Department, University Hospital "Città della Salute e della Scienza di Torino", Corso Dogliotti 14, 10126, Turin, Italy.
  • Parasiliti-Caprino M; Division of Endocrinology, Diabetology and Metabolism, Medical Science Department, University Hospital "Città della Salute e della Scienza di Torino", Corso Dogliotti 14, 10126, Turin, Italy.
  • Gasco V; Division of Endocrinology, Diabetology and Metabolism, Medical Science Department, University Hospital "Città della Salute e della Scienza di Torino", Corso Dogliotti 14, 10126, Turin, Italy.
  • Ghigo E; Division of Endocrinology, Diabetology and Metabolism, Medical Science Department, University Hospital "Città della Salute e della Scienza di Torino", Corso Dogliotti 14, 10126, Turin, Italy.
  • Grottoli S; Division of Endocrinology, Diabetology and Metabolism, Medical Science Department, University Hospital "Città della Salute e della Scienza di Torino", Corso Dogliotti 14, 10126, Turin, Italy.
J Endocrinol Invest ; 45(10): 1955-1965, 2022 Oct.
Article en En | MEDLINE | ID: mdl-35748978
PURPOSE: This study aims to compare the accuracy of mean GH profile (GHP) < 2.5 ng/ml and single fasting GH (SGH) < 1 ng/ml in the evaluation of disease control in acromegaly patients during somatostatin receptor ligands (SRLs) therapy. METHODS: We retrospectively enrolled 100 acromegaly patients, 68 responder, and 32 partial responder to SRLs. Controlled disease has been defined as IGF-I levels within age-related normal limits, while partial response as pathological IGF-I values despite a reduction ≥ 50%. In all patients, GHP, SGH, IGF-I, and IGFBP-3 were evaluated. RESULTS: Median GHP levels (1.2 ng/ml, IQR 0.5-2.3 ng/ml) were lower (p = 0.001) than SGH (1.9 ng/ml, IQR 1.0-3.6 ng/ml). Accuracy of GHP was 81%, whereas that of SGH was 55%, with a Kappa index of 0.520 and 0.237, respectively. In multivariable analysis GHP (p = 0.002) and IGFBP-3 (p = 0.004), but not SGH, were independently associated with normal IGF-I levels. At receiver-operator characteristic curve (ROC) analysis GHP cut-off sensitivity and specificity were 94.1% and 50.0%, respectively, while SGH sensitivity and specificity were 35.3% and 93.7%, respectively. Finally, in obese patients the GH cut-off level (both as SGH and GHP) associated to good disease control was significantly different with respect to not obese ones. CONCLUSIONS: GHP associates with IGF-I (and therefore with appropriate control of disease) with higher accuracy than SGH. When GH evaluation is needed, the measurement of mean GHP should be preferred and use of BMI-related cut-offs is suggested.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Acromegalia / Hormona de Crecimiento Humana Tipo de estudio: Observational_studies Límite: Humans Idioma: En Revista: J Endocrinol Invest Año: 2022 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Italia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Acromegalia / Hormona de Crecimiento Humana Tipo de estudio: Observational_studies Límite: Humans Idioma: En Revista: J Endocrinol Invest Año: 2022 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Italia